Report Detail

Uveitis is the third leading cause of blindness worldwide. The most common type of uveitis is an inflammation of the iris called iritis (anterior uveitis). Uveitis can damage vital eye tissue, leading to permanent vision loss.
Market Insights

Due to the COVID-19 pandemic, the global Non-infectious Anterior Uveitis Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028.

The global main manufacturers of Non-infectious Anterior Uveitis Treatment include Bausch & Lomb, Santen Pharmaceutical, AbbVie, OKYO, Novartis, Eyegate Pharmaceuticals, Regeneron Pharmaceuticals, Eyepoint pharmaceuticals and Alimera Sciences. etc. In 2021, the global six largest players have a share approximately % in terms of revenue.

The North America Non-infectious Anterior Uveitis Treatment market is estimated at US$ million in 2021, while China is forecast to reach US$ million by 2028. The proportion of the China is % in 2021 and it is predicted that the share will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. As for the Europe Non-infectious Anterior Uveitis Treatment landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

Corticosteroid Drug accounting for % of the Non-infectious Anterior Uveitis Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.

Segment Scope

An intensive study of key type and application segments has been done in this segmentation section. The authors of the report have provided reliable figures including sales and revenue forecast data by type and application for the period 2017-2028. They have also studied how the segments are gaining or losing growth in various geographies and their respective countries. Thanks to this study, readers can thoroughly grasp the growth pattern and potential of different segments.

Segment by Type

Corticosteroid Drug

Immunosuppressant Drug

Others

Segment by Application

Hospitals

Eye Clinics

Home Treatment

Others

Regional Scope

This segment of the report offers a thorough regional study of the global Non-infectious Anterior Uveitis Treatment market. Drivers and restraints for each region are broadly examined in the report. Readers will get familiar with the driving forces and challenges that are specific to the regions. The specialists have identified growth opportunities in key geographical regions and their respective countries to aid players to reinforce their presence. All the regions and their countries in the report are assessed based on the growth rate, revenue, and sales volume according to the consumption for the period 2017-2028. This geographical analysis will help readers to gain in-depth knowledge of the regional growth. The key geographical regions surveyed in this research report involve North America, Europe, Asia Pacific, Central and South America, and Middle East and Africa. The report has specifically covered major countries including United States, Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.

Key Players

This section has provided an exhaustive analysis of the strategies that the companies are focusing on to stay ahead of other players. The strategies mainly involve research and development, new product developments, and mergers and acquisitions. The researchers have also provided revenue shares of the key companies, company overview, and the latest company developments so as to help players to sustain the cutthroat competition. In this section, the report offers global revenue and sales data of manufacturers for the period 2017-2022. Following is the list of key manufacturers observed in this research study:

Bausch & Lomb

Santen Pharmaceutical

AbbVie

OKYO

Novartis

Eyegate Pharmaceuticals

Regeneron Pharmaceuticals

Eyepoint pharmaceuticals

Alimera Sciences

Frequently Asked Questions

Which application segment captured the leading share in the Non-infectious Anterior Uveitis Treatment market?

How fragmented is the Non-infectious Anterior Uveitis Treatment market?

Which are the key growth drivers in the Non-infectious Anterior Uveitis Treatment market?

Which are the top strategies undertaken by the Non-infectious Anterior Uveitis Treatment market players?

Which technological trends are likely to affect the Non-infectious Anterior Uveitis Treatment market?

What is the expected Non-infectious Anterior Uveitis Treatment market size by 2028?

Which companies are dominating the Non-infectious Anterior Uveitis Treatment market?

Which region is projected to witness the fastest growth in the future?

What factors are restraining the Non-infectious Anterior Uveitis Treatment market growth?

Which are the emerging companies in the Non-infectious Anterior Uveitis Treatment market?


1 Non-infectious Anterior Uveitis Treatment Market Overview

  • 1.1 Non-infectious Anterior Uveitis Treatment Product Overview
  • 1.2 Non-infectious Anterior Uveitis Treatment Market Segment by Type
  • 1.2.1 Corticosteroid Drug
  • 1.2.2 Immunosuppressant Drug
  • 1.2.3 Others
  • 1.3 Global Non-infectious Anterior Uveitis Treatment Market Size by Type
  • 1.3.1 Global Non-infectious Anterior Uveitis Treatment Market Size Overview by Type (2017-2028)
  • 1.3.2 Global Non-infectious Anterior Uveitis Treatment Historic Market Size Review by Type (2017-2022)
  • 1.3.2.1 Global Non-infectious Anterior Uveitis Treatment Sales Breakdown in Volume by Type (2017-2022)
  • 1.3.2.2 Global Non-infectious Anterior Uveitis Treatment Sales Breakdown in Value by Type (2017-2022)
  • 1.3.2.3 Global Non-infectious Anterior Uveitis Treatment Average Selling Price (ASP) by Type (2017-2022)
  • 1.3.3 Global Non-infectious Anterior Uveitis Treatment Forecasted Market Size by Type (2023-2028)
  • 1.3.3.1 Global Non-infectious Anterior Uveitis Treatment Sales Breakdown in Volume by Type (2023-2028)
  • 1.3.3.2 Global Non-infectious Anterior Uveitis Treatment Sales Breakdown in Value by Type (2023-2028)
  • 1.3.3.3 Global Non-infectious Anterior Uveitis Treatment Average Selling Price (ASP) by Type (2023-2028)
  • 1.4 Key Regions Market Size Segment by Type
  • 1.4.1 North America Non-infectious Anterior Uveitis Treatment Sales Breakdown by Type (2017-2022)
  • 1.4.2 Europe Non-infectious Anterior Uveitis Treatment Sales Breakdown by Type (2017-2022)
  • 1.4.3 Asia-Pacific Non-infectious Anterior Uveitis Treatment Sales Breakdown by Type (2017-2022)
  • 1.4.4 Latin America Non-infectious Anterior Uveitis Treatment Sales Breakdown by Type (2017-2022)
  • 1.4.5 Middle East and Africa Non-infectious Anterior Uveitis Treatment Sales Breakdown by Type (2017-2022)
  • 2 Global Non-infectious Anterior Uveitis Treatment Market Competition by Company

    • 2.1 Global Top Players by Non-infectious Anterior Uveitis Treatment Sales (2017-2022)
    • 2.2 Global Top Players by Non-infectious Anterior Uveitis Treatment Revenue (2017-2022)
    • 2.3 Global Top Players Non-infectious Anterior Uveitis Treatment Price (2017-2022)
    • 2.4 Global Top Manufacturers Non-infectious Anterior Uveitis Treatment Manufacturing Base Distribution, Sales Area, Product Type
    • 2.5 Non-infectious Anterior Uveitis Treatment Market Competitive Situation and Trends
    • 2.5.1 Non-infectious Anterior Uveitis Treatment Market Concentration Rate (2017-2022)
  • 2.5.2 Global 5 and 10 Largest Manufacturers by Non-infectious Anterior Uveitis Treatment Sales and Revenue in 2021
  • 2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Non-infectious Anterior Uveitis Treatment as of 2021)
  • 2.7 Date of Key Manufacturers Enter into Non-infectious Anterior Uveitis Treatment Market
  • 2.8 Key Manufacturers Non-infectious Anterior Uveitis Treatment Product Offered
  • 2.9 Mergers & Acquisitions, Expansion
  • 3 Non-infectious Anterior Uveitis Treatment Status and Outlook by Region

    • 3.1 Global Non-infectious Anterior Uveitis Treatment Market Size and CAGR by Region: 2017 VS 2021 VS 2028
    • 3.2 Global Non-infectious Anterior Uveitis Treatment Historic Market Size by Region
    • 3.2.1 Global Non-infectious Anterior Uveitis Treatment Sales in Volume by Region (2017-2022)
  • 3.2.2 Global Non-infectious Anterior Uveitis Treatment Sales in Value by Region (2017-2022)
  • 3.2.3 Global Non-infectious Anterior Uveitis Treatment Sales (Volume & Value) Price and Gross Margin (2017-2022)
  • 3.3 Global Non-infectious Anterior Uveitis Treatment Forecasted Market Size by Region
  • 3.3.1 Global Non-infectious Anterior Uveitis Treatment Sales in Volume by Region (2023-2028)
  • 3.3.2 Global Non-infectious Anterior Uveitis Treatment Sales in Value by Region (2023-2028)
  • 3.3.3 Global Non-infectious Anterior Uveitis Treatment Sales (Volume & Value), Price and Gross Margin (2023-2028)
  • 4 Global Non-infectious Anterior Uveitis Treatment by Application

    • 4.1 Non-infectious Anterior Uveitis Treatment Market Segment by Application
    • 4.1.1 Hospitals
  • 4.1.2 Eye Clinics
  • 4.1.3 Home Treatment
  • 4.1.4 Others
  • 4.2 Global Non-infectious Anterior Uveitis Treatment Market Size by Application
  • 4.2.1 Global Non-infectious Anterior Uveitis Treatment Market Size Overview by Application (2017-2028)
  • 4.2.2 Global Non-infectious Anterior Uveitis Treatment Historic Market Size Review by Application (2017-2022)
  • 4.2.2.1 Global Non-infectious Anterior Uveitis Treatment Sales Breakdown in Volume, by Application (2017-2022)
  • 4.2.2.2 Global Non-infectious Anterior Uveitis Treatment Sales Breakdown in Value, by Application (2017-2022)
  • 4.2.2.3 Global Non-infectious Anterior Uveitis Treatment Average Selling Price (ASP) by Application (2017-2022)
  • 4.2.3 Global Non-infectious Anterior Uveitis Treatment Forecasted Market Size by Application (2023-2028)
  • 4.2.3.1 Global Non-infectious Anterior Uveitis Treatment Sales Breakdown in Volume, by Application (2023-2028)
  • 4.2.3.2 Global Non-infectious Anterior Uveitis Treatment Sales Breakdown in Value, by Application (2023-2028)
  • 4.2.3.3 Global Non-infectious Anterior Uveitis Treatment Average Selling Price (ASP) by Application (2023-2028)
  • 4.3 Key Regions Market Size Segment by Application
  • 4.3.1 North America Non-infectious Anterior Uveitis Treatment Sales Breakdown by Application (2017-2022)
  • 4.3.2 Europe Non-infectious Anterior Uveitis Treatment Sales Breakdown by Application (2017-2022)
  • 4.3.3 Asia-Pacific Non-infectious Anterior Uveitis Treatment Sales Breakdown by Application (2017-2022)
  • 4.3.4 Latin America Non-infectious Anterior Uveitis Treatment Sales Breakdown by Application (2017-2022)
  • 4.3.5 Middle East and Africa Non-infectious Anterior Uveitis Treatment Sales Breakdown by Application (2017-2022)
  • 5 North America Non-infectious Anterior Uveitis Treatment by Country

    • 5.1 North America Non-infectious Anterior Uveitis Treatment Historic Market Size by Country
    • 5.1.1 North America Non-infectious Anterior Uveitis Treatment Sales in Volume by Country (2017-2022)
  • 5.1.2 North America Non-infectious Anterior Uveitis Treatment Sales in Value by Country (2017-2022)
  • 5.2 North America Non-infectious Anterior Uveitis Treatment Forecasted Market Size by Country
  • 5.2.1 North America Non-infectious Anterior Uveitis Treatment Sales in Volume by Country (2023-2028)
  • 5.2.2 North America Non-infectious Anterior Uveitis Treatment Sales in Value by Country (2023-2028)
  • 6 Europe Non-infectious Anterior Uveitis Treatment by Country

    • 6.1 Europe Non-infectious Anterior Uveitis Treatment Historic Market Size by Country
    • 6.1.1 Europe Non-infectious Anterior Uveitis Treatment Sales in Volume by Country (2017-2022)
  • 6.1.2 Europe Non-infectious Anterior Uveitis Treatment Sales in Value by Country (2017-2022)
  • 6.2 Europe Non-infectious Anterior Uveitis Treatment Forecasted Market Size by Country
  • 6.2.1 Europe Non-infectious Anterior Uveitis Treatment Sales in Volume by Country (2023-2028)
  • 6.2.2 Europe Non-infectious Anterior Uveitis Treatment Sales in Value by Country (2023-2028)
  • 7 Asia-Pacific Non-infectious Anterior Uveitis Treatment by Region

    • 7.1 Asia-Pacific Non-infectious Anterior Uveitis Treatment Historic Market Size by Region
    • 7.1.1 Asia-Pacific Non-infectious Anterior Uveitis Treatment Sales in Volume by Region (2017-2022)
  • 7.1.2 Asia-Pacific Non-infectious Anterior Uveitis Treatment Sales in Value by Region (2017-2022)
  • 7.2 Asia-Pacific Non-infectious Anterior Uveitis Treatment Forecasted Market Size by Region
  • 7.2.1 Asia-Pacific Non-infectious Anterior Uveitis Treatment Sales in Volume by Region (2023-2028)
  • 7.2.2 Asia-Pacific Non-infectious Anterior Uveitis Treatment Sales in Value by Region (2023-2028)
  • 8 Latin America Non-infectious Anterior Uveitis Treatment by Country

    • 8.1 Latin America Non-infectious Anterior Uveitis Treatment Historic Market Size by Country
    • 8.1.1 Latin America Non-infectious Anterior Uveitis Treatment Sales in Volume by Country (2017-2022)
  • 8.1.2 Latin America Non-infectious Anterior Uveitis Treatment Sales in Value by Country (2017-2022)
  • 8.2 Latin America Non-infectious Anterior Uveitis Treatment Forecasted Market Size by Country
  • 8.2.1 Latin America Non-infectious Anterior Uveitis Treatment Sales in Volume by Country (2023-2028)
  • 8.2.2 Latin America Non-infectious Anterior Uveitis Treatment Sales in Value by Country (2023-2028)
  • 9 Middle East and Africa Non-infectious Anterior Uveitis Treatment by Country

    • 9.1 Middle East and Africa Non-infectious Anterior Uveitis Treatment Historic Market Size by Country
    • 9.1.1 Middle East and Africa Non-infectious Anterior Uveitis Treatment Sales in Volume by Country (2017-2022)
  • 9.1.2 Middle East and Africa Non-infectious Anterior Uveitis Treatment Sales in Value by Country (2017-2022)
  • 9.2 Middle East and Africa Non-infectious Anterior Uveitis Treatment Forecasted Market Size by Country
  • 9.2.1 Middle East and Africa Non-infectious Anterior Uveitis Treatment Sales in Volume by Country (2023-2028)
  • 9.2.2 Middle East and Africa Non-infectious Anterior Uveitis Treatment Sales in Value by Country (2023-2028)
  • 10 Company Profiles and Key Figures in Non-infectious Anterior Uveitis Treatment Business

    • 10.1 Bausch & Lomb
    • 10.1.1 Bausch & Lomb Corporation Information
  • 10.1.2 Bausch & Lomb Introduction and Business Overview
  • 10.1.3 Bausch & Lomb Non-infectious Anterior Uveitis Treatment Sales, Revenue and Gross Margin (2017-2022)
  • 10.1.4 Bausch & Lomb Non-infectious Anterior Uveitis Treatment Products Offered
  • 10.1.5 Bausch & Lomb Recent Development
  • 10.2 Santen Pharmaceutical
  • 10.2.1 Santen Pharmaceutical Corporation Information
  • 10.2.2 Santen Pharmaceutical Introduction and Business Overview
  • 10.2.3 Santen Pharmaceutical Non-infectious Anterior Uveitis Treatment Sales, Revenue and Gross Margin (2017-2022)
  • 10.2.4 Santen Pharmaceutical Non-infectious Anterior Uveitis Treatment Products Offered
  • 10.2.5 Santen Pharmaceutical Recent Development
  • 10.3 AbbVie
  • 10.3.1 AbbVie Corporation Information
  • 10.3.2 AbbVie Introduction and Business Overview
  • 10.3.3 AbbVie Non-infectious Anterior Uveitis Treatment Sales, Revenue and Gross Margin (2017-2022)
  • 10.3.4 AbbVie Non-infectious Anterior Uveitis Treatment Products Offered
  • 10.3.5 AbbVie Recent Development
  • 10.4 OKYO
  • 10.4.1 OKYO Corporation Information
  • 10.4.2 OKYO Introduction and Business Overview
  • 10.4.3 OKYO Non-infectious Anterior Uveitis Treatment Sales, Revenue and Gross Margin (2017-2022)
  • 10.4.4 OKYO Non-infectious Anterior Uveitis Treatment Products Offered
  • 10.4.5 OKYO Recent Development
  • 10.5 Novartis
  • 10.5.1 Novartis Corporation Information
  • 10.5.2 Novartis Introduction and Business Overview
  • 10.5.3 Novartis Non-infectious Anterior Uveitis Treatment Sales, Revenue and Gross Margin (2017-2022)
  • 10.5.4 Novartis Non-infectious Anterior Uveitis Treatment Products Offered
  • 10.5.5 Novartis Recent Development
  • 10.6 Eyegate Pharmaceuticals
  • 10.6.1 Eyegate Pharmaceuticals Corporation Information
  • 10.6.2 Eyegate Pharmaceuticals Introduction and Business Overview
  • 10.6.3 Eyegate Pharmaceuticals Non-infectious Anterior Uveitis Treatment Sales, Revenue and Gross Margin (2017-2022)
  • 10.6.4 Eyegate Pharmaceuticals Non-infectious Anterior Uveitis Treatment Products Offered
  • 10.6.5 Eyegate Pharmaceuticals Recent Development
  • 10.7 Regeneron Pharmaceuticals
  • 10.7.1 Regeneron Pharmaceuticals Corporation Information
  • 10.7.2 Regeneron Pharmaceuticals Introduction and Business Overview
  • 10.7.3 Regeneron Pharmaceuticals Non-infectious Anterior Uveitis Treatment Sales, Revenue and Gross Margin (2017-2022)
  • 10.7.4 Regeneron Pharmaceuticals Non-infectious Anterior Uveitis Treatment Products Offered
  • 10.7.5 Regeneron Pharmaceuticals Recent Development
  • 10.8 Eyepoint pharmaceuticals
  • 10.8.1 Eyepoint pharmaceuticals Corporation Information
  • 10.8.2 Eyepoint pharmaceuticals Introduction and Business Overview
  • 10.8.3 Eyepoint pharmaceuticals Non-infectious Anterior Uveitis Treatment Sales, Revenue and Gross Margin (2017-2022)
  • 10.8.4 Eyepoint pharmaceuticals Non-infectious Anterior Uveitis Treatment Products Offered
  • 10.8.5 Eyepoint pharmaceuticals Recent Development
  • 10.9 Alimera Sciences
  • 10.9.1 Alimera Sciences Corporation Information
  • 10.9.2 Alimera Sciences Introduction and Business Overview
  • 10.9.3 Alimera Sciences Non-infectious Anterior Uveitis Treatment Sales, Revenue and Gross Margin (2017-2022)
  • 10.9.4 Alimera Sciences Non-infectious Anterior Uveitis Treatment Products Offered
  • 10.9.5 Alimera Sciences Recent Development
  • 11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis

    • 11.1 Non-infectious Anterior Uveitis Treatment Key Raw Materials
    • 11.1.1 Key Raw Materials
  • 11.1.2 Key Raw Materials Price
  • 11.1.3 Raw Materials Key Suppliers
  • 11.2 Manufacturing Cost Structure
  • 11.2.1 Raw Materials
  • 11.2.2 Labor Cost
  • 11.2.3 Manufacturing Expenses
  • 11.3 Non-infectious Anterior Uveitis Treatment Industrial Chain Analysis
  • 11.4 Non-infectious Anterior Uveitis Treatment Market Dynamics
  • 11.4.1 Non-infectious Anterior Uveitis Treatment Industry Trends
  • 11.4.2 Non-infectious Anterior Uveitis Treatment Market Drivers
  • 11.4.3 Non-infectious Anterior Uveitis Treatment Market Challenges
  • 11.4.4 Non-infectious Anterior Uveitis Treatment Market Restraints
  • 12 Market Strategy Analysis, Distributors

    • 12.1 Sales Channel
    • 12.2 Non-infectious Anterior Uveitis Treatment Distributors
    • 12.3 Non-infectious Anterior Uveitis Treatment Downstream Customers

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
      • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
    • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
    • 14.2 Author Details
    • Summary:
      Get latest Market Research Reports on Non-infectious Anterior Uveitis Treatment. Industry analysis & Market Report on Non-infectious Anterior Uveitis Treatment is a syndicated market report, published as Global Non-infectious Anterior Uveitis Treatment Market Report, History and Forecast 2017-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. It is complete Research Study and Industry Analysis of Non-infectious Anterior Uveitis Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,350.00
      $6,700.00
      2,636.45
      5,272.90
      3,085.35
      6,170.70
      523,303.50
      1,046,607.00
      279,155.50
      558,311.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report